v3.26.1
Statement of Cash Flows - Veraxa Biotech Holding A G [Member]
6 Months Ended
Dec. 31, 2025
CHF (SFr)
CASH FLOWS FROM OPERATING ACTIVITIES:  
Net loss SFr (26,856)
Adjustments to reconcile net loss to net cash provided by operating activities:  
Accrued Expenses 18,000
Due to related party 8,856
Advances-related parties 1,000
Net cash provided by operating activities 1,000
CASH FLOWS FROM FINANCING ACTIVITIES:  
Proceeds from initial capital contribution 100,000
Net cash provided by financing activities 100,000
NET CHANGE IN CASH 101,000
Cash, beginning of period
Cash, end of period SFr 101,000